Cogent Biosciences Soars 120% on Breakthrough Phase 3 Results for Bezuclastinib in GIST Treatment 
Trump Signs Executive Order to Boost AI Research in Childhood Cancer 
Is space worth the cost? Accounting experts say its value can’t be found in spreadsheets 
Dollar Slides to Five-Week Low as Asian Stocks Struggle and Markets Bet on Fed Rate Cut 
Netflix Nearing Major Deal to Acquire Warner Bros Discovery Assets 
Tesla Expands Affordable Model 3 Lineup in Europe to Boost EV Demand 
FDA Pilot Program Eases Rules for Nicotine Pouch Makers 
Novartis to Acquire Avidity Biosciences for $12 Billion to Strengthen Rare Muscle Disorder Portfolio 
Tesla Faces 19% Drop in UK Registrations as Competition Intensifies 
Pfizer Boosts Bid for Metsera Amid Intensifying Rivalry with Novo Nordisk in Obesity Drug Market 
GM Issues Recall for 2026 Chevrolet Silverado Trucks Over Missing Owner Manuals 
U.S. Experts to Reassess Newborn Hepatitis B Vaccination Guidelines Amid Growing Debate 
Asian Markets Mixed as Fed Rate Cut Bets Grow and Japan’s Nikkei Leads Gains 
Dollar Weakens Ahead of Expected Federal Reserve Rate Cut 
Pfizer Secures $10 Billion Deal for Obesity Drug Developer Metsera, Outbids Novo Nordisk 
JW Pharmaceutical will use the zebrafish to develop new drugs and expand indications of its drug candidates.
To expedite the process, the South Korean drug developer has inked a memorandum of understanding (MOU) with Zefit, a domestic non-clinical trial institute that specializes in zebrafish models.
Zefit will provide disease-specific zebrafish models using gene editing technology and a drug screening platform.
Zebrafish, a tropical fish species whose genetic structure is more than 80 percent similar to humans, is increasingly being used as a non-clinical intermediary research model.
Zebrafish can replace mammalian experiments, according to Zefit.
Conducting experiments with zebrafish can bring down costs to about one-tenth of those for mammals.
JW Pharmaceutica plans to use zebrafish to bridge the gap between non-clinical and clinical research.
Zebrafish experiments can be 91 percent similar to those conducted with mammals.
According to Shin Jun-nyeong, CEO of Zefit, Interest in zebrafish is increasing among regulatory agencies such as the US Food and Drug Administration (FDA).
